Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Author
:
KN Chi
A Protheroe
A Rodríguez-Antolín
G Facchini
H Suttman
N Matsubara
Z Ye
B Keam
R Damião
T Li
K McQuarrie
B Jia
P De Porre
J Martin
MB Todd
K Fizazi
Abstract
:

In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study.
Year of Publication
:
2018
Journal
:
The Lancet. Oncology
Date Published
:
2018
ISSN Number
:
1470-2045
DOI
:
10.1016/S1470-2045(17)30911-7
Short Title
:
Lancet Oncol
Download citation